Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
Conditions:
HIV Infections
Sponsor: Boehringer Ingelheim
trial.available_in:
БГ
Overview
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.
Who can participate
Inclusion criteria:
Patients aho have a positive serology HIV antibody test confirmed by Western blot, p24 antigen assay, HIV-1 RNA or HIV culture and are highly pre-treated and virus resistant to multiple protease inhibitors.
Locations
12
Australia (1)
1182.58.61005 Royal Prince Alfred Hospital
Camperdown , New South Wales
Belgium (1)
1182.58.3201 Boehringer Ingelheim Investigational Site
Antwerp
Denmark (1)
1182.58.4505 Aarhus Universitetshospital Skejby
Aarhus C
France (1)
1182.58.33029 Hôpital Aix
Aix-en-Provence
Greece (1)
1182.58.3001
Athens
Ireland (1)
1182.58.44016 St James Hospital, Dept of Genito Urinary Medicine
Dublin
Italy (1)
1182.58.3903 Università di Brescia
Brescia
Portugal (1)
1182.58.35102 Hospital Condes Castro Guimarães
Cascais
South Africa (1)
1182.58.27095 Boehringer Ingelheim Investigational Site
Cape Town
Switzerland (1)
1182.58.4101 Boehringer Ingelheim Investigational Site
БГ